AMNEAL PHARMACEUTICALS, INC. (AMRX) Spending and interest coverage
- R&D / revenue · 12 months: Value 5.63%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.14%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 5.63% | Research and development expense / revenue. Period ending 2026-06-30. $175.57M ÷ $3.12B × 100 ≈ 5.63% |
| Stock-based compensation / revenue · 12 months | 1.14% | Share-based compensation / revenue. Period ending 2026-06-30. $35.63M ÷ $3.12B × 100 ≈ 1.14% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 175.57M USD | Research and Development Expense |
| Revenue | 3.12B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 35.63M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 453.92M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $175.57M | $3.12B | $35.63M | $453.92M | (m) | 5.63% | 1.14% | (m) | (m) |
| 2026-03-31 | $184.52M | $3.05B | $33.51M | $435.52M | (m) | 6.06% | 1.10% | (m) | (m) |
| 2025-12-31 | $186.18M | $3.02B | $31.95M | $394.10M | (m) | 6.17% | 1.06% | (m) | (m) |
| 2025-09-30 | $205.62M | $2.93B | $30.96M | $357.86M | (m) | 7.01% | 1.05% | (m) | (m) |
| 2025-06-30 | $203.37M | $2.85B | $29.85M | $376.32M | (m) | 7.13% | 1.05% | (m) | (m) |
| 2025-03-31 | $191.46M | $2.83B | $28.30M | $360.42M | (m) | 6.76% | 1.00% | (m) | (m) |
| 2024-12-31 | $190.71M | $2.79B | $27.77M | $249.33M | (m) | 6.83% | 0.99% | (m) | (m) |
| 2024-09-30 | $182.53M | $2.68B | $26.53M | $187.73M | (m) | 6.81% | 0.99% | (m) | (m) |
| 2024-06-30 | $162.81M | $2.60B | $26.11M | $174.56M | (m) | 6.27% | 1.01% | (m) | (m) |
| 2024-03-31 | $164.56M | $2.50B | $25.95M | $159.18M | (m) | 6.59% | 1.04% | (m) | (m) |
| 2023-12-31 | $163.95M | $2.39B | $26.82M | $204.37M | (m) | 6.85% | 1.12% | (m) | (m) |
| 2023-09-30 | $159.77M | $2.39B | $28.68M | $226.21M | (m) | 6.70% | 1.20% | (m) | (m) |
| 2023-06-30 | $168.63M | $2.31B | $29.68M | $194.92M | (m) | 7.29% | 1.28% | (m) | (m) |
| 2023-03-31 | $181.58M | $2.27B | $31.38M | $-83.78M | (m) | 7.99% | 1.38% | (m) | (m) |
| 2022-12-31 | $195.69M | $2.21B | $31.85M | $-94.93M | (m) | 8.85% | 1.44% | (m) | (m) |
| 2022-09-30 | $205.66M | $2.14B | $31.76M | $-119.78M | (m) | 9.61% | 1.48% | (m) | (m) |
| 2022-06-30 | $204.35M | $2.12B | $31.78M | $-135.62M | (m) | 9.63% | 1.50% | (m) | (m) |
| 2022-03-31 | $206.46M | $2.10B | $31.15M | $130.11M | (m) | 9.84% | 1.48% | (m) | (m) |
| 2021-12-31 | $201.85M | $2.09B | $28.41M | $152.72M | (m) | 9.64% | 1.36% | (m) | (m) |
| 2021-09-30 | $203.43M | $2.07B | $25.80M | $161.72M | (m) | 9.84% | 1.25% | (m) | (m) |
| 2021-06-30 | $199.03M | $2.06B | $23.51M | $135.64M | (m) | 9.67% | 1.14% | (m) | (m) |
| 2021-03-31 | $191.73M | $1.99B | $21.54M | $79.27M | (m) | 9.65% | 1.08% | (m) | (m) |
| 2020-12-31 | $179.93M | $1.99B | $20.75M | $91.16M | (m) | 9.03% | 1.04% | (m) | (m) |
| 2020-09-30 | $174.52M | $1.88B | $20.63M | $47.84M | (m) | 9.28% | 1.10% | (m) | (m) |
| 2020-06-30 | $168.13M | $1.74B | $21.31M | $-66.87M | (m) | 9.67% | 1.23% | (m) | (m) |
| 2020-03-31 | $170.57M | $1.68B | $21.87M | $-96.53M | (m) | 10.16% | 1.30% | (m) | (m) |
| 2019-12-31 | $188.05M | $1.63B | $21.68M | $-248.68M | (m) | 11.56% | 1.33% | (m) | (m) |
| 2019-09-30 | $197.30M | $1.73B | $20.27M | $-202.27M | (m) | 11.43% | 1.17% | (m) | (m) |
| 2019-06-30 | $201.52M | $1.82B | $17.77M | $-15.44M | (m) | 11.04% | 0.97% | (m) | (m) |
| 2019-03-31 | $203.84M | $1.83B | $171.94M | $-177.59M | (m) | 11.11% | 9.38% | (m) | (m) |
| 2018-12-31 | $194.19M | $1.66B | $167.60M | $-19.67M | (m) | 11.68% | 10.08% | (m) | (m) |
| 2018-09-30 | (m) | $890.27M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $1.08B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $171.42M | $1.03B | $0.00 | $245.10M | (m) | 16.58% | 0.00% | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $179.02M | $1.02B | $0.00 | $284.88M | (m) | 17.58% | 0.00% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |